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Abstract
Background: Current treatments for the prevention of thromboembolism include heparin and low-molecular
weight heparins (LMWHs). A number of studies have suggested that long term administration of these drugs may
adversely affect osteoblasts and therefore, bone metabolism. Xarelto™ (Rivaroxaban) is a new anti-thrombotic drug
for the prevention of venous thromboembolism in adult patients undergoing elective hip and knee replacement
surgery. The aim of this in vitro study was to investigate the possible effects of rivaroxaban on osteoblast viability,
function and gene expression compared to enoxaparin, a commonly used LMWH.
Methods: Primary human osteoblast cultures were treated with varying concentrations of rivaroxaban (0.013, 0.13,
1.3 and 13 μg/ml) or enoxaparin (1, 10 and 100 μg/ml). The effect of each drug on osteoblast function was
evaluated by measuring alkaline phosphatase activity. The MTS assay was used to assess the effect of drug
treatments on cell proliferation. Changes in osteocalcin, Runx2 and BMP-2 messenger RNA (mRNA) expression
following drug treatments were measured by real-time polymerase chain reaction (PCR).
Results: Rivaroxaban and enoxaparin treatment did not adversely affect osteoblast viability. However, both drugs
caused a significant reduction in osteoblast function, as measured by alkaline phosphatase activity. This reduction
in osteoblast function was associated with a reduction in the mRNA expression of the bone marker, osteocalcin,
the transcription factor, Runx2, and the osteogenic factor, BMP-2.
Conclusions: These data show that rivaroxaban treatment may negatively affect bone through a reduction in
osteoblast function.
Background
Venous thromboembolism is a significant potential
complication following orthopaedic surgery and an
important cause of morbidity and mortality in adults. In
the absence of thromboprophylaxis, the rate of deep
vein thrombosis following major lower extremity ortho-
paedic surgery is between 40-60%, while the risk of
developing fatal pulmonary embolism is between 1-2%
[1,2]. Current treatments for the prevention of venous
thromboembolism include heparin and low-molecular
weight heparins (LMWHs). While heparin and LMWH
therapy are effective measures for the prevention of
thromboembolism, a number of studies have suggested
that long term administration may negatively affect
bone and some have associated their use with the risk
of developing osteoporosis [3,4]. Although heparin-
induced osteoporosis is a rare adverse effect, its inci-
dence is thought to be in the range of 2-5% [5]. Studies
have shown that prolonged unfractionated heparin treat-
ment is associated with bone loss and an increased risk
of fracture [6,7]. Studies have also shown that women
who receive extended heparin therapy during pregnancy,
have significant reduction of bone density in their lum-
bar spines [8]. There is some evidence to suggest that
LMWH may have a reduced incidence of osteopenia
and osteoporosis when compared with unfractionated
heparin therapy [3].
Rivaroxaban or Xarelto™ (Bayer Schering Pharma
AG) is an anti-thrombotic drug that was granted mar-
keting approval by the European Commission
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prevention of venous thromboembolism in adult
patients undergoing elective hip and knee replacement
surgery [9]. A direct Factor Xa inhibitor, this drug
represents an attractive alternative to heparin and
LMWH for the purposes of prophylactic anti-coagula-
tion as it is administered orally and thus removes the
need for daily injections.
Rivaroxaban therapy is recommended for 5 weeks post
hip replacement surgery and 2 weeks post knee replace-
ment surgery [10]. In light of the fact that heparin and
LMWHs have been associated with adverse effects on
bone and a risk of developing osteoporosis, the aim of
this study was to investigate the effects of rivaroxaban,
compared with enoxaparin, on human osteoblasts in
vitro. The effect of each drug was evaluated in terms of
its effect on osteoblast viability, function and gene
expression.
Methods
Osteoblast cell culture and treatment
A human osteoblast cell line (primary cells) was pur-
chased from PromoCell (Heidelberg, Germany). Osteo-
blasts were isolated from bone biopsies (cancellous bone)
obtained from the femoral condyles of the knee joint of a
patient undergoing knee surgery (N =1 ,7 8y e a ro l d ,
Caucasian female). Osteoblast cells were characterised by
the supplier as staining positive for alkaline phosphatase
and osteocalcin. Cells were routinely cultured in Osteo-
blast Growth Media (C-27001; Promocell, Germany) at
37°C in a humidified atmosphere of 95% air and 5% CO2.
Growth media contained 10% fetal calf serum, 125 μg/ml
sodium phosphate and 50 μg/ml ascorbic acid. Cells were
seeded into 6-well plates at a density of 1 × 10
5 cells
(alkaline phosphatase assay, PCR analysis) or into 96-well
plates at a density of 5 × 10
4 cells per well (cell viability
assay). Cells were then cultured to approximately 80%
confluence prior to treatment.
Osteoblast cells were cultured in the presence of enox-
aparin (Clexane™, 100 IU/mg anti-Xa activity; Sanofi
Aventis) at concentrations of 1, 10 and 100 μg/ml. Cells
cultured in the presence of osteoblast growth medium
alone served as experimental controls. Rivaroxaban (BAY
59-7939) was obtained directly from Bayer
® pharmaceu-
ticals (Germany) in aliquots containing 10 mg of rivarox-
aban salt. Rivaroxaban was dissolved in dimethyl
sulphoxide (DMSO; Sigma, Ireland) as demonstrated in
previous in vitro studies with this drug [11]. Final rivar-
oxaban concentrations were obtained by dilution in cul-
ture media and were as follows: 0.013, 0.13, 1.3 and 13
μg/ml, which included the mean in vivo therapeutic
range (0.02 - 0.05 μg/ml) [12]. Cells cultured in media
containing equivalent amounts of DMSO as treatments
served as experimental controls for the rivaroxaban
group. DMSO concentrations for each concentration of
rivaroxaban treated cells were 0.182, 1.82, 18.2 and 182
mM, respectively. The need for two control groups was
necessary as rivaroxaban required additional DMSO as a
solvent while enoxaparin was completely soluble in
osteoblast growth medium alone. During the one week
treatment period, the culture medium was replaced every
72 hours with medium containing the test drug.
Cell viability analysis
Cell viability was assessed using the CellTiter 96
® AQu-
eous One Solution Cell Proliferation Assay (Promega,
UK) as per manufacturer’s instructions and previous lit-
erature [13]. It is a colorimetric assay and contains a tet-
razolium compound that, when reduced, produces a
colored formazan product that is soluble in cell culture
medium and absorbs maximally at 490 nm. The com-
pound is reduced as a result of the mitochondrial activ-
i t yi nt h ec e l l s ,a n dt h ea m o u n to ff o r m a z a nt h a ti s
produced is directly proportional to the number of
viable cells Cells were seeded into 96-well plates at a
d e n s i t yo f5×1 0
4 cells/well and cultured at 37°C in a
humidified incubator containing 5% CO2. Once approxi-
mately 80% confluent, cells were treated for 72 hours
with varying concentrations of enoxaparin or rivaroxa-
ban and their respective controls. A 20 μl aliquot of the
CellTitre 96
® Aqueous One Solution reagent was added
to each culture well and after 4 hours the absorbance
was recorded at 490 nm. The cell viability of treatment
cultures was reported as a percentage of control cul-
tures. All assays were carried out in triplicate.
Assay for alkaline phosphatase activity
Alkaline phosphatase activity was measured as a marker
of osteoblast function. Cells were seeded into 6-well
plates at a density of 1 × 10
5 cells/well. Following 7 days
of treatment with enoxaparin or rivaroxaban and their
respective controls, cell lysates were collected by CelLy-
tic M (Sigma, UK) and the extracted proteins frozen at
-80°C. The alkaline phosphatase activity of cell lysates
was determined using a p-nitrophenylphosphate (pNPP)
based assay [14]. A 5 μl aliquot of cell lysate was incu-
bated with 100 μl of p-NPP solution for 30 minutes at
37°C and the absorbance at 405 nm was recorded using
a plate reader. Alkaline phosphatase activity was nor-
malised to total protein, which was determined using
the Bradford assay. The alkaline phosphatase activity of
treatment cultures was expressed as a percentage of
control cultures (n = 6; 6 independant cultures from a
single donor cell source).
RNA isolation and real-time PCR
Total cellular RNA was extracted from osteoblasts trea-
ted with enoxaparin or rivaroxaban and their respective
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ing to the manufacturer’s instructions. Contaminating
genomic DNA was removed from RNA samples using a
DNA-free™ kit (Applied Biosystems, UK). RNA was
reverse transcribed to complementary DNA (cDNA)
using the Enhanced Avian Reverse Transcriptase kit
(Sigma, Ireland). cDNA served as template for real-time
PCR, which was conducted using the QIAGEN Quanti-
Tect SYBR Green PCR kit (Qiagen, UK). Using gene
specific primer pairs, the mRNA expression of the runt-
related transcription factor 2 (Runx2), bone morphoge-
netic protein-2 (BMP-2) and Osteocalcin (OC) gene
products were measured using absolute quantification
and were reported as a function of crossing time (Ct),
the cycle number at which PCR amplification becomes
linear. mRNA expression was normalised to control and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression resulting in mean fold change values. Assays
were carried out in triplicate (3 independent cDNA pre-
parations extracted from 3 independent cultures) (Table
1 Table 2).
Statistical Analysis
Data are given as a mean ± standard deviation. Data
were analysed using Student’s t-test to determine a sig-
nificant difference between sample means. Differences
were considered significant if P < 0.05.
Results
Effect of enoxaparin and rivaroxaban on osteoblast cell
viability
From the results of the CellTiter 96
® AQueous One
Solution Cell Proliferation Assay (Promega, UK), cells
treated with enoxaparin were found to have a similar
viability when compared to control cells (Figure 1). Riv-
aroxaban treatment did not have an adverse effect on
osteoblast viability, however, cells treated with the lower
concentrations of rivaroxaban (0.013 and 0.13 μg/ml)
showed a significant increase in viability of 15% and
10%, respectively (Figure 1).
Table 1 Forward and reverse primers used in real-time
PCR analysis
Gene Forward Reverse
Runx2 5’-TTACTTACACCCCGCCAGTC-
3’
5’-TATGGAGTGCTGCTGGTCTG-
3’
BMP-2 5’-
TCAAGCCAAACACAAACAGC-
3’
5’-AGCCACAATCCAGTCATTCC-
3’
OC 5’-GACTGTGACGAGTTGGCTG
-3’
5’-
CTGGAGAGGAGCAGAACTGG-
3’
GAPDH 5’-GAGTCAACGGATTTGGTCGT-
3’
5’-TTGATTTTGGAGGGATCTCG-
3’
Table 2 Average Ct values obtained for GAPDH during
RT-PCR analysis
Average Ct
Day 1 Day 7
Control 17.35 18.32
Enoxaparin 1 μg/ml 16.67 18.68
Enoxaparin 10 μg/ml 16.47 16.86
Enoxaparin 100 μg/ml 17.70 17.33
DMSO 0.182 mM 17.05 19.81
DMSO 1.82 mM 17.27 16.96
DMSO 18.2 mM 17.22 17.48
DMSO 182 mM 16.66 17.32
Rivaroxaban 0.013 μg/ml 16.07 17.68
Rivaroxaban 0.13 μg/ml 17.08 16.58
Rivaroxaban 1.3 μg/ml 16.72 15.32
Rivaroxaban 13 μg/ml 16.51 15.84
Figure 1 Effect of enoxaparin and rivaroxaban on cell viability
of human osteoblast cultures. Human osteoblast cells were
cultured in the presence of varying concentrations of (A) enoxaparin
and (B) rivaroxaban for 72 hours after which cell viability was
assessed using the MTS assay. Percent viable cells (y) are presented
as a proportion of the viability of control cultures. Data are
presented as the mean ± the standard deviation. *p < 0.05 from
Student’s t-test relative to the control treatment (n = 3).
Solayar et al. BMC Musculoskeletal Disorders 2011, 12:247
http://www.biomedcentral.com/1471-2474/12/247
Page 3 of 8Effect of enoxaparin and rivaroxaban on osteoblast
function
To determine the functional effect of enoxaparin and
rivaroxaban treatment we measured the alkaline phos-
phatase activity after 7 days of treatment. Enoxaparin
treatment induced a dose-dependent reduction in alka-
line phosphatase activity, a well-established marker of
osteoblast function (Figure 2). This reduction in alkaline
phosphatase activity ranged from 35% +/-18% (p <
0.0001) to 50% +/- 19% (p < 0.0001). Rivaroxaban treat-
ment resulted in a dramatic decrease in alkaline phos-
phatase activity at each of the concentrations tested
when compared to control cultures (Figure 2). The low-
est concentration of rivaroxaban caused a significant
reduction in alkaline phosphatase activity (57% +/- 15%,
p < 0.0001), with further reductions observed in the pre-
sence of higher rivaroxaban concentrations [0.13 μg/ml
(69% +/- 10%, p < 0.0001) and [1.3 μg/ml (68% +/- 9%,
p < 0.0001)]. When therapeutic levels of enoxaparin (1-
10 μg/ml) and rivaroxaban (0.013-0.13 μg/ml) were
compared, alkaline phosphatase activity was found to be
significantly less in rivaroxaban-treated cultures at both
the lower and higher therapeutic levels (enoxaparin 1
μg/ml versus rivaroxaban 0.013 μg/ml, p < 0.0005; enox-
aparin 10 μg/ml versus rivaroxaban 0.13 μg/ml, p <
0.001).
Effect of rivaroxaban and enoxaparin on osteocalcin
expression
To examine the effect of enoxaparin and rivaroxaban on
osteocalcin, a marker of bone formation, we measured
osteocalcin mRNA expression by real-time PCR follow-
ing treatment with both drugs. Changes in gene expres-
sion were measured after 1 and 7 days in order to
examine the immediate and long term effect of drug
treatments. As shown in Figure 3 enoxaparin treatment
Figure 2 Effect of enoxaparin and rivaroxaban on human
osteoblast function. Human osteoblast cultures were treated with
varying concentrations of enoxaparin and rivaroxaban for 7 days
and then analysed for alkaline phosphatase activity. The alkaline
phosphatase activity of treatment cultures is expressed as a
percentage of untreated controls. Data are presented as the mean
± the standard deviation. *p < 0.05; **p < 0.01 from Student’s t-test
relative to the control treatment (n = 6).
Figure 3 (A&B) - Effect of enoxaparin and rivaroxaban on
osteocalcin mRNA expression in human osteoblast cultures.
Following 1 and 7 days of treatment, osteoblast cultures were
analysed for changes in osteocalcin mRNA expression using RT-PCR.
Data are presented as mean fold change ± the standard deviation.
*p < 0.05; **p < 0.01 from Student’s t-test relative to the control
treatment (n = 3).
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sion at both time-points, however, this reduction was not
statistically significant. Rivaroxaban treatment resulted in
a reduction in osteocalcin expression at all concentra-
tions tested with a statistically significant reduction
observed in the presence of higher rivaroxaban concen-
trations (0.13 - 13 μg/ml) after 7 days (Figure 3).
Effect of enoxaparin and rivaroxaban treatment on Runx2
and BMP-2 expression
We next determined the effect of both drugs on the
major osteoblast transcription factor, Runx2, and the
pro-osteogenic growth factor, BMP-2. A significant
reduction in Runx2 mRNA expression was observed in
cultures treated with the highest concentration of enox-
aparin (100 μg/ml), and in cultures treated with a range
of rivaroxaban concentrations, including the therapeutic
levels (Figure 4 and 4). A significant reduction in BMP-
2 mRNA expression was observed after 1 and 7 days of
treatment in all enoxaparin and rivaroxaban treated cul-
tures, as is illustrated in Figure 4 and 4.
Discussion
Long term administration of heparin and LMWH has
been associated with a negative effect on bone and an
increased risk of developing osteoporosis [3,4]. Xar-
elto™ (Rivaroxaban) is a new anti-thrombotic drug that
was recently licensed for the prevention of venous
thromboembolism in adult patients undergoing elective
hip and knee replacement surgery. At present, the
effects of rivaroxaban on bone and osteoblasts are
unknown. In this study, we investigated the effect of riv-
aroxaban on human osteoblasts in terms of its effect on
viability, function and gene expression. Acute and
chronic changes in gene expression were measured after
1 and 7 days treatment whereas the functional markers
(alkaline phosphatase) were measured following 7 days
of treatment. In addition, the effects induced by rivarox-
aban were compared to those induced by enoxaparin, a
commonly used LMWH. The principal finding of this
study was that, rivaroxaban treatment leads to a reduc-
tion in osteoblast function, as measured by alkaline
phosphate activity, and that this was associated with
Figure 4 The effect of enoxaparin and rivaroxaban concentration on Runx2 and BMP2 mRNA expression following 1 and 7 days of
treatment. Data are presented as mean fold change ± the standard deviation. *p < 0.05; **p < 0.01 from Student’s t-test relative to the control
treatment (n = 3).
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major osteoblast factor, Runx2, and the osteogenic fac-
tor, BMP-2.
Clinical trials comparing the efficacy and side effects
of enoxaparin and rivaroxaban therapy on the outcome
of thrombosis following joint replacement surgery
favour the use of rivaroxaban for the prevention of
thrombotic events post-arthroplasty (RECORD trials)
[10]. This, coupled with the fact that rivaroxaban is
available orally (eliminating the need for invasive admin-
istration), makes the use of rivaroxaban an attractive
option for both orthopaedic surgeons and patients alike.
Enoxaparin is generally administered for 5 to 7 days in
the immediate post-operative period while the patient
remains in hospital. In the case of rivaroxaban, therapy
is recommended for 5 weeks post hip replacement sur-
gery and 2 weeks post knee replacement surgery [10].
As long term administration of heparin and LMWH has
been associated with reduced bone mineral density
[8,15] and increased fracture rates in pregnant women
[16,17], we investigated the effect of rivaroxaban on
human osteoblasts.
In this study, neither enoxaparin nor rivaroxaban
treatment caused a reduction in osteoblast cell viability
indicating that both drugs do not show cytotoxic effects
to osteoblasts studied. Our findings in relation to enoxa-
parin are in accordance with those of other studies,
which have shown that enoxaparin does not have a
cytotoxic effect on osteoblast viability [18]. Similarly,
other low molecular weight heparins, such as fondapari-
nux, do not induce cytotoxic effects on osteoblast prolif-
eration [19]. However, while rivaroxaban and
enoxaparin treatment did not reduce osteoblast prolif-
eration, both drugs caused a reduction of an established
marker of osteoblast function: alkaline phosphatase. The
bone-specific isoform of alkaline phosphatase is a tetra-
meric glycoprotein found on the surface of osteoblast
cells and is believed to have a significant function in the
mineralization of bone matrix [20]. Previous studies
have shown that heparin and low-molecular-weight
heparins, such as enoxaparin, exert a negative effect on
alkaline phosphatase expression [21,22]. In the present
study, both enoxaparin and rivaroxaban treatment
caused a significant reduction in osteoblast alkaline
phosphatase activity, with rivaroxaban causing a more
negative effect. Osteocalcin is another commonly used
marker of bone formation/turnover [23]. Osteocalcin
expression was also reduced by enoxaparin and rivarox-
aban treatment. This decrease was found to be statisti-
cally significant following treatment with rivaroxaban for
7 days indicating that prolonged rivaroxaban therapy
may have a negative impact on osteoblast function.
Our findings of reduced alkaline phosphatase activity
and osteocalcin expression in the absence of reduced
cell viability suggested that enoxaparin and rivaroxaban
treatment may negatively affect bone through a reduc-
tion in osteoblast function rather than a decrease in
osteoblast proliferation. Therefore, to determine if rivar-
oxaban and enoxaparin influence osteoblast function
through changes in osteoblast signalling, the expression
of the transcription factor, Runx2, and the pro-osteo-
genic growth factor, BMP-2 were investigated. The
exposure of human osteoblasts to enoxaparin and rivar-
oxaban resulted in a significant reduction of both Runx2
and BMP-2 expression in this study. Runx2 is the main
transcription factor responsible for the development and
maintenance of the osteoblast phenotype [24] and tar-
geted disruption of this gene in mice leads to a com-
plete lack of ossification [25]. The expression and
activation of the Runx2 transcription factor is regulated
by a number of bone-derived growth factors, including
BMP-2 [26]. BMP2 has previously been shown to play a
crucial role in bone formation and repair [27], and also
in the regulation of osteoclastogenesis [28].
These findings suggest that enoxaparin and rivaroxa-
ban may affect osteoblast function by reducing BMP-2
induced bone formation. Since the exposure of human
osteoblasts to both drugs did not result in a cytotoxic
affect in this study, a downregulation of BMP-2 signal-
ling may explain the reduction in osteoblast functional-
ity. Runx2 regulates the expression of several major
extracellular matrix genes expressed by osteoblasts
including alkaline phosphatase and osteocalcin [29,30].
Thus, a reduction in BMP-2 and Runx2 signalling, could
lead to a reduction in alkaline phosphatase activity and
osteocalcin expression, and ultimately lead to an impair-
ment of osteoblast function. Studies have demonstrated
that heparin can inhibit BMP-2 osteogenic activity by
binding to both the BMP-2 and BMP receptor, and this
effect has been associated with reduced Runx2, osteocal-
cin and alkaline phosphatase expression [31]. However,
this type of BMP-2 mediated repression has not been
reported in relation to enoxaparin or rivaroxaban.
Bone metabolism is a continuous remodelling process
involving both bone formation by osteoblasts and bone
resorption by osteoclasts. Heparin has been found to
negatively affect bone formation by promoting the acti-
vation of osteoclasts and decreasing bone volume in
rats, by inducing bone resorption in rat osteoclasts in
vitro [32,33] and enhancing osteoclastic bone resorption
through an inhibition of osteoprotegerin activity [34].
While the effect of enoxaparin and rivaroxaban on
osteoclast function was not investigated as part of this
study, our study confirmed that both thromboprophy-
lactic agents negatively affect osteoblast function. Such
findings indicate that long term therapy with enoxaparin
or rivaroxaban could potentially translate into clinical
effects on bone homeostasis.
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In conclusion, rivaroxaban and enoxaparin treatment led
to a reduction in alkaline phosphatase activity and a
reduction in BMP-2, osteocalcin and Runx2 mRNA
expression, indicating that treatment with both drugs
leads to a general negative effect on osteoblast activity.
Due to the increased duration of therapy (as compared
to enoxaparin), rivaroxaban could potentially be more
detrimental than enoxaparin in terms of its effects on
osteoblast function. While the findings of this study
indicate that rivaroxaban negatively affects osteoblast
function, further clinical investigations are required to
elucidate whether these effects of rivaroxaban therapy
translate into demonstrable effects on bone homeostasis
in vivo. Given that these agents are typically promoted
for use following hip and knee arthroplasty, and that
many modern hip and knee implants are ‘uncemented’
and depend on effective bone ingrowth for fixation,
these findings are of potential clinical importance.
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